Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia

被引：2
|
作者：
El Kinge, Abdul Rahman
Hatourn, Hassan A.
Mahfouz, Rami A. [2 ]
Otrock, Zaher K. [2 ]
Jabbour, Elias [3 ]
Kantarjian, Hagop [3 ]
Bazarbachi, Ali [1 ]
机构：
[1] Amer Univ Beirut, Med Ctr, Dept Internal Med, Bone Marrow Transplantat Program, Beirut, Lebanon
[2] Amer Univ Beirut, Med Ctr, Dept Pathol & Lab Med, Beirut, Lebanon
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷 / 04期
关键词：
ACUTE MYELOGENOUS LEUKEMIA; RELAPSE; CHEMOTHERAPY; PROPOSAL;
D O I：
10.1016/j.leukres.2008.05.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：565 / 566
页数：2
相关论文
共 50 条
  • [21] Low-dose Gemtuzumab-Ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study
    Poloni, Antonella
    Capelli, Debora
    Trappolini, Silvia
    Costantini, Benedetta
    Montanari, Mauro
    Gini, Guido
    Scortechini, Ilaria
    Mancini, Giorgia
    Discepoli, Giancarlo
    Leoni, Pietro
    Olivieri, Attilio
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (01) : 119 - 121
  • [22] Lyon-University Hospital Experience with Gemtuzumab Ozogamicin Therapy in Acute Myeloid Leukemia: a 'Real-Life' Study
    Laurino, Marica
    Loron, Sandrine
    Larcher, Marie-Virginie
    Fossard, Gaelle
    Elhamri, Mohamed
    Deloire, Alexandre
    Balsat, Marie
    Barraco, Fiorenza
    Labussiere, Helene
    Ducastelle, Sophie
    Renault, Myriam
    Wattel, Eric
    Heiblig, Mael
    Salles, Gilles
    Thomas, Xavier
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2020, 12
  • [23] Gemtuzumab Ozogamicin Can Reduce Minimal Residual Disease in Patients With Childhood Acute Myeloid Leukemia
    O'Hear, Carol
    Inaba, Hiroto
    Pounds, Stanley
    Shi, Lei
    Dahl, Gary
    Bowman, W. Paul
    Taub, Jeffrey W.
    Pui, Ching-Hon
    Ribeiro, Raul C.
    Coustan-Smith, Elaine
    Campana, Dario
    Rubnitz, Jeffrey E.
    CANCER, 2013, 119 (22) : 4036 - 4043
  • [24] Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia
    Cortes, Jorge E.
    de Lima, Marcos
    Dombret, Herve
    Estey, Elihu H.
    Giralt, Sergio A.
    Montesinos, Pau
    Roellig, Christoph
    Venditti, Adriano
    Wang, Eunice S.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [25] Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience
    Hosono, Naoko
    Ookura, Miyuki
    Araie, Hiroaki
    Morita, Mihoko
    Itoh, Kazuhiro
    Matsuda, Yasufumi
    Yamauchi, Takahiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (03) : 362 - 369
  • [26] Re-analysis of the Outcomes of Post-Remission Therapy for Acute Myeloid Leukemia with Core Binding Factor According to Years of Patient Enrolment
    Shin, Ho-Jin
    Kim, Hyeoung-Joon
    Sohn, Sang Kyun
    Min, Yoo Hong
    Won, Jong-Ho
    Kim, Inho
    Yoon, Hwi-Joong
    Lee, Jae Hoon
    Jo, Deog-Yeon
    Joo, Young Don
    Jung, Chul Won
    Lee, Kyoo-Hyung
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (06) : 556 - 566
  • [27] Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy
    Thomas, X
    Le, QH
    De Botton, S
    Raffoux, E
    Chelghoum, Y
    Pautas, C
    Dreyfus, F
    Dhedin, N
    Vekhoff, A
    Troncy, J
    Pigneux, A
    De Revel, T
    Reman, O
    Travade, P
    Thiebaut, A
    Guerci, A
    Elhamri, M
    Fenaux, P
    Dombret, H
    Michallet, M
    LEUKEMIA & LYMPHOMA, 2005, 46 (07) : 1007 - 1016
  • [28] An adjuvanted whole cell vaccine as post-remission immunotherapy for acute leukemia
    Weinkove, Robert
    Ancelet, Lindsay R.
    Gibbins, John D.
    Hermans, Ian F.
    ONCOIMMUNOLOGY, 2015, 4 (04):
  • [29] New agents in post-remission therapy
    Stone, Richard M.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2010, 23 (04) : 475 - 479
  • [30] Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF
    Martin, Mike G.
    Augustin, Kristan M.
    Uy, Geoffrey L.
    Welch, John S.
    Hladnik, Lindsay
    Goyal, Sagun
    Tiwari, Divya
    Monahan, Ryan S.
    Reichley, Richard M.
    Cashen, Amanda F.
    Stockerl-Goldstein, Keith
    Westervelt, Peter
    Abboud, Camille N.
    DiPersio, John F.
    Vij, Ravi
    AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (11) : 733 - 737
12345